These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
371 related articles for article (PubMed ID: 35976445)
1. Triple negative breast cancer: approved treatment options and their mechanisms of action. Mandapati A; Lukong KE J Cancer Res Clin Oncol; 2023 Jul; 149(7):3701-3719. PubMed ID: 35976445 [TBL] [Abstract][Full Text] [Related]
2. Perspectives on Triple-Negative Breast Cancer: Current Treatment Strategies, Unmet Needs, and Potential Targets for Future Therapies. Gupta GK; Collier AL; Lee D; Hoefer RA; Zheleva V; Siewertsz van Reesema LL; Tang-Tan AM; Guye ML; Chang DZ; Winston JS; Samli B; Jansen RJ; Petricoin EF; Goetz MP; Bear HD; Tang AH Cancers (Basel); 2020 Aug; 12(9):. PubMed ID: 32846967 [TBL] [Abstract][Full Text] [Related]
3. Intense dose-dense epirubicin, paclitaxel, cyclophosphamide versus weekly paclitaxel, liposomal doxorubicin (plus carboplatin in triple-negative breast cancer) for neoadjuvant treatment of high-risk early breast cancer (GeparOcto-GBG 84): A randomised phase III trial. Schneeweiss A; Möbus V; Tesch H; Hanusch C; Denkert C; Lübbe K; Huober J; Klare P; Kümmel S; Untch M; Kast K; Jackisch C; Thomalla J; Ingold-Heppner B; Blohmer JU; Rezai M; Frank M; Engels K; Rhiem K; Fasching PA; Nekljudova V; von Minckwitz G; Loibl S Eur J Cancer; 2019 Jan; 106():181-192. PubMed ID: 30528802 [TBL] [Abstract][Full Text] [Related]
4. Differential response of immunohistochemically defined breast cancer subtypes to anthracycline-based adjuvant chemotherapy with or without paclitaxel. Fountzilas G; Dafni U; Bobos M; Batistatou A; Kotoula V; Trihia H; Malamou-Mitsi V; Miliaras S; Chrisafi S; Papadopoulos S; Sotiropoulou M; Filippidis T; Gogas H; Koletsa T; Bafaloukos D; Televantou D; Kalogeras KT; Pectasides D; Skarlos DV; Koutras A; Dimopoulos MA PLoS One; 2012; 7(6):e37946. PubMed ID: 22679488 [TBL] [Abstract][Full Text] [Related]
5. Novel Therapies for Metastatic Triple-Negative Breast Cancer: Spotlight on Immunotherapy and Antibody-Drug Conjugates. Nagayama A; Vidula N; Bardia A Oncology (Williston Park); 2021 May; 35(5):249-254. PubMed ID: 33983696 [TBL] [Abstract][Full Text] [Related]
6. Progress and pitfalls in the use of immunotherapy for patients with triple negative breast cancer. Agostinetto E; Losurdo A; Nader-Marta G; Santoro A; Punie K; Barroso R; Popovic L; Solinas C; Kok M; de Azambuja E; Lambertini M Expert Opin Investig Drugs; 2022 Jun; 31(6):567-591. PubMed ID: 35240902 [TBL] [Abstract][Full Text] [Related]
7. Small Molecule Therapeutics in the Pipeline Targeting for Triple-Negative Breast Cancer: Origin, Challenges, Opportunities, and Mechanisms of Action. James N; Owusu E; Rivera G; Bandyopadhyay D Int J Mol Sci; 2024 Jun; 25(11):. PubMed ID: 38892472 [TBL] [Abstract][Full Text] [Related]
8. Targeted Therapies and the Evolving Standard of Care for Triple-Negative and Germline Desai NV; Tan AR JCO Precis Oncol; 2023 May; 7():e2200446. PubMed ID: 37163718 [TBL] [Abstract][Full Text] [Related]
9. Adjuvant Capecitabine in Combination With Docetaxel, Epirubicin, and Cyclophosphamide for Early Breast Cancer: The Randomized Clinical FinXX Trial. Joensuu H; Kellokumpu-Lehtinen PL; Huovinen R; Jukkola-Vuorinen A; Tanner M; Kokko R; Ahlgren J; Auvinen P; Lahdenperä O; Kosonen S; Villman K; Nyandoto P; Nilsson G; Poikonen-Saksela P; Kataja V; Junnila J; Bono P; Lindman H JAMA Oncol; 2017 Jun; 3(6):793-800. PubMed ID: 28253390 [TBL] [Abstract][Full Text] [Related]
10. Autophagy inhibition augments the anticancer effects of epirubicin treatment in anthracycline-sensitive and -resistant triple-negative breast cancer. Chittaranjan S; Bortnik S; Dragowska WH; Xu J; Abeysundara N; Leung A; Go NE; DeVorkin L; Weppler SA; Gelmon K; Yapp DT; Bally MB; Gorski SM Clin Cancer Res; 2014 Jun; 20(12):3159-73. PubMed ID: 24721646 [TBL] [Abstract][Full Text] [Related]
11. Nodal expression in triple-negative breast cancer: Cellular effects of its inhibition following doxorubicin treatment. Bodenstine TM; Chandler GS; Reed DW; Margaryan NV; Gilgur A; Atkinson J; Ahmed N; Hyser M; Seftor EA; Strizzi L; Hendrix MJ Cell Cycle; 2016 May; 15(9):1295-302. PubMed ID: 27007464 [TBL] [Abstract][Full Text] [Related]
12. Survival analysis of the randomised phase III GeparOcto trial comparing neoadjuvant chemotherapy of intense dose-dense epirubicin, paclitaxel, cyclophosphamide versus weekly paclitaxel, liposomal doxorubicin (plus carboplatin in triple-negative breast cancer) for patients with high-risk early breast cancer. Schneeweiss A; Michel LL; Möbus V; Tesch H; Klare P; Hahnen E; Denkert C; Kast K; Pohl-Rescigno E; Hanusch C; Link T; Untch M; Jackisch C; Blohmer JU; Fasching PA; Solbach C; Schmutzler RK; Huober J; Rhiem K; Nekljudova V; Lübbe K; Loibl S; Eur J Cancer; 2022 Jan; 160():100-111. PubMed ID: 34801353 [TBL] [Abstract][Full Text] [Related]
13. In vitro chemoresponse assay based on the intrinsic subtypes in breast cancer. Gwe Ahn S; Ah Lee S; Woo Lee H; Min Lee H; Jeong J Jpn J Clin Oncol; 2014 Jul; 44(7):624-31. PubMed ID: 24803548 [TBL] [Abstract][Full Text] [Related]
14. State of art of advanced triple negative breast cancer. Khosravi-Shahi P; Cabezón-Gutiérrez L; Aparicio Salcedo MI Breast J; 2019 Sep; 25(5):967-970. PubMed ID: 31155832 [TBL] [Abstract][Full Text] [Related]
15. Atezolizumab and pembrolizumab in triple-negative breast cancer: a meta-analysis. Latif F; Bint Abdul Jabbar H; Malik H; Sadaf H; Sarfraz A; Sarfraz Z; Cherrez-Ojeda I Expert Rev Anticancer Ther; 2022 Feb; 22(2):229-235. PubMed ID: 34949142 [TBL] [Abstract][Full Text] [Related]
16. Immunotherapy in triple-negative breast cancer. Katz H; Alsharedi M Med Oncol; 2017 Dec; 35(1):13. PubMed ID: 29255938 [TBL] [Abstract][Full Text] [Related]
17. Emerging CAR-T Cell Therapy for the Treatment of Triple-Negative Breast Cancer. Dees S; Ganesan R; Singh S; Grewal IS Mol Cancer Ther; 2020 Dec; 19(12):2409-2421. PubMed ID: 33087511 [TBL] [Abstract][Full Text] [Related]
18. The evolving management of metastatic triple negative breast cancer. Malhotra MK; Emens LA Semin Oncol; 2020 Aug; 47(4):229-237. PubMed ID: 32563561 [TBL] [Abstract][Full Text] [Related]
20. Research advances and new challenges in overcoming triple-negative breast cancer. Zong Y; Pegram M Cancer Drug Resist; 2021; 4(3):517-542. PubMed ID: 34888495 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]